Altoida Software for Alzheimer's Disease Gains Breakthrough Designation

Altoida’s precision neurology software for prediction of Alzheimer's disease and dementia has received the FDA’s Breakthrough Device designation.

Users age 55 and older with mild cognitive impairment complete a 10-minute set of “augmented reality and motor activities” on their smartphone or tablet, and the software predicts if the individuals will or will not progress to Alzheimer's disease within 12 months.

Altoida, which is based in Houston, Tex., and Lucerne, Switzerland, recently entered into a partnership with Eisai Innovation, a strategic investment subsidiary of pharma giant Eisai, to accelerate its predictive dementia diagnostics work.